Profile: Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

35.49EUR
4:26am EDT
Price Change (% chg)

€0.04 (+0.10%)
Prev Close
€35.46
Open
€35.49
Day's High
€35.56
Day's Low
€35.28
Volume
46,436
Avg. Vol
743,758
52-wk High
€42.53
52-wk Low
€28.25

Search Stocks
Grifols SA is a Spain-based company engaged in the healthcare sector. The Company is involved in the research, development, manufacturing and marketing of medical solutions for hospitals, which include plasma-derived therapies, as well as diagnosis and pharmaceutical products. Its activities are structured in four segments: Bioscience, which focuses on the research for obtaining new therapies and solutions aimed at patients who suffer from illnesses stemming from plasma deficits; Diagnostic, which comprises the research, development and marketing of diagnostic products for clinical laboratories, Hospital, which offers ready-to-use pharmaceutical preparations and products for clinical nutrition; and Raw Materials, which includes sales of biological products and services. The Company is a parent of Grupo Grifols. On January 9, 2014, it acquired a diagnostic unit from Novartis International AG. In June 2014, the Company has opened new North Fractionation Facility (NFF) in Clayton.

Company Address

Grifols SA

C/ Jesus i Maria, 6
BARCELONA   BAR   08022
P: +34935.710100
F: +34935.710267

Search Stocks